心臓弁装置の世界市場 - 2025年～2033年

心臓弁装置の世界市場は2024年に127億6,000万米ドルに達し、2033年には346億米ドルに達すると予測され、予測期間2025年から2033年のCAGRは12.34%で成長する見込みです。

心臓弁装置心臓弁は、損傷したり病気になったりした心臓の弁を交換したり修復したりするために使用される医療機器であり、心臓の部屋を通る一方向の血流を確保するために不可欠です。人間の心臓には、僧帽弁、三尖弁、肺動脈弁、大動脈弁の4つの主要な弁があります。これらの弁は心周期の圧力変化に応じて開閉し、血液が心房から心室へ、そして体外へ逆流することなくスムーズに流れるようにします。心臓弁膜症は、狭窄（弁の収縮）や逆流（弁の漏れ）などの障害により、これらの弁が正常に機能しなくなることで発症し、心不全を含む大きな健康問題につながります。

心臓弁装置に対する需要の増加は、予測期間中の市場を牽引する要因です。この需要の急増は、主にライフスタイルの変化や人口の高齢化に伴って一般的になりつつある心血管疾患の頻度の増加によるものです。多くの人が大動脈弁狭窄症などの問題を治療するために心臓弁の手術を必要とするため、新規の機器に対する需要が高まっています。ヘルスケア技術が進歩し、より低侵襲な処置が可能になるにつれて、心臓弁装置市場は大きく成長すると予想されます。

市場力学：

促進要因と抑制要因

心臓弁装置需要の増加

心臓弁装置に対する需要の増加は、心臓弁装置の世界市場成長の重要な要因になると予測されます。心臓弁装置の需要は、心血管疾患の有病率の上昇、技術の進歩、心臓弁装置に関する意識の高まり、最近の発売や承認によって増加しています。

個人が高齢になり、肥満や座りがちな行動などのライフスタイルに関連した危険因子がより頻繁になるにつれて、心臓弁膜症の有病率が上昇します。心血管障害の有病率の上昇に伴い、新たな解決策が必要とされ、正常な心臓機能を回復させ、患者の予後を改善できる心臓弁装置への需要が高まっています。例えば、米国疾病予防管理センターによると、心臓病は米国の男性、女性、そしてほとんどの人種や民族の人々の主な死因となっています。米国では33秒に1人が心血管疾患で死亡しています。米国では約695,000人が心臓病で死亡しており、これは死亡者5人に1人の割合です。

さらに、3Dプリンティング技術の進歩は、特定の患者の解剖学的構造に基づいたカスタムメイドの心臓弁インプラントの製造に変革をもたらしました。このようなカスタマイズは、フィット感と機能性を向上させ、より良い臨床結果につながります。さらに、患者自身の細胞やドナー組織を用いて天然の弁構造を再現することに重点を置いた、生体工学的心臓弁の研究も進行中です。この戦略は、合成材料に伴う拒絶反応や長期的な困難を軽減することを目的としています。心臓血管の研究開発への継続的な投資は、このような技術の進歩をより深化させる原動力となっています。各機関が既存の心臓弁装置の革新と改良に取り組むと同時に、生体適合性と性能の向上を約束する革新的な素材やデザインも研究されています。

最近では、最新技術を駆使して製造された製品が発売されています。例えば、2024年6月、ヘルスケア技術の世界的リーダーであるメドトロニック社は、心臓手術における最新のイノベーションであるアバラスウルトラ弁（Avalus Ultra valve）の発売を発表しました。この次世代手術用大動脈組織弁は、留置時の使いやすさと患者の生涯管理を容易にするよう設計されています。心臓外科医とその患者にとって、最初から将来に適合できる大動脈弁ソリューションを求める優れた選択肢です。

手技や機器にかかる高額な費用

処置やデバイスのコストが高いといった要因が、世界の心臓弁装置市場を阻害すると予想されます。主な問題の一つは、心臓弁の処置、特に経カテーテル大動脈弁置換術（TAVR）のような最新技術に伴う大きな価格負担です。これらの治療には、機器自体の費用だけでなく、術前画像診断、入院、術後ケアなどの追加費用が頻繁に含まれます。こうした高額な費用のために、多くの患者、特に低・中所得地域の患者や十分な保険が適用されない患者は、必要な治療を受けることが難しくなります。その結果、経済的な負担が患者の迅速な治療への意欲を削ぎ、市場の総需要を減少させる可能性があります。

例えば、米国国立衛生研究所によると、機械弁と生体弁を用いた弁置換術の自己負担額の中央値は、それぞれINR107,800（US$1684）とINR154,000（US$2406）、バルーン弁切開術の自己負担額はINR14,456（US$367）と推定されています。機械的弁置換術、生体弁置換術、バルーン弁切開術の1回あたりのパッケージ全体の費用は、それぞれINR127,919（US$1999）、INR148,919（US$2372）、INR14,456（US$226）と推定されました。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
  • 心臓弁装置の需要増加
  • 抑制要因
  • 処置と機器の高額な費用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 償還分析
• 特許分析
• SWOT分析
• DMIの見解

第6章 心臓弁置換装置別

• 機械弁
• 生体弁
• TAVR

第7章 ポジション別

• 僧帽弁
• 大動脈弁
• その他

第8章 心臓弁修復装置別

• 外科用弁
• バルーン弁形成術用デバイス
• TMVR

第9章 エンドユーザー別

• 病院
• 外来手術センター
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• Abbott
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Medtronic
• Artivion, Inc
• Boston Scientific Corporation
• Micro Interventional Devices
• Edwards Lifesciences Corporation
• Sorin Medical Group
• TTK Heartvalve
• JenaValve
• Lepu Medical Technology（Beijing）Co., Ltd.

第13章 付録

The global heart valve devices market reached US$ 12.76 billion in 2024 and is expected to reach US$ 34.6 billion by 2033, growing at a CAGR of 12.34% during the forecast period 2025-2033.

Heart valve devices are medical devices used to replace or repair damaged or diseased heart valves, which are essential for ensuring unidirectional blood flow through the heart's chambers. The human heart has four primary valves, the mitral valve, tricuspid valve, pulmonary valve, and aortic valve. These valves open and close in response to pressure changes during the cardiac cycle, ensuring that blood flows smoothly from the atria to the ventricles and out to the body with no backflow. Heart valve disease occurs when these valves fail to function properly due to disorders such as stenosis (valve constriction) or regurgitation (leakage), leading to major health issues including heart failure.

The increasing demand for heart valve devices is the driving factor that drives the market over the forecast period. The surge in demand is due to this surge is primarily due to an increase in the frequency of cardiovascular diseases, which are becoming more common as lifestyles change and populations age. Many individuals require heart valve procedures to treat problems such as aortic stenosis, creating a greater demand for novel devices. As healthcare technology progresses and more minimally invasive procedures become available, the market for heart valve devices is expected to grow significantly.

Market Dynamics: Drivers & Restraints

Increasing demand for heart valve devices

The increasing demand for heart valve devices is expected to be a significant factor in the growth of the global heart valve devices market. The demand for heart valve devices is increasing owing to the rising prevalence of cardiovascular diseases, technological advancements, growing awareness regarding heart valve devices, and recent launches and approvals.

As individuals grow older and lifestyle-related risk factors such as obesity and sedentary behavior become more frequent, the prevalence of heart valve problems rises. The rising prevalence of cardiovascular disorders needs novel solutions, fueling demand for heart valve devices that can restore normal heart function and improve patient outcomes. For instance, according to the Centers for Disease Control and Prevention, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. One person dies every 33 seconds in the United States from cardiovascular disease. About 695,000 people in the United States died from heart disease, that's 1 in every 5 deaths.

Furthermore, advances in 3D printing technology have transformed the manufacturing of custom-made heart valve implants based on specific patient anatomy. This amount of customization improves fit and functionality, leading to better clinical outcomes. Furthermore, research on bioengineered heart valves is underway, with an emphasis on reproducing natural valve structures using a patient's own cells or donor tissues. This strategy is intended to reduce rejection and long-term difficulties associated with synthetic materials. Continuous investment in cardiovascular research and development drives these technological advancements to greater depths. As organizations work to innovate and improve existing heart valve devices, they are also investigating innovative materials and designs that promise improved biocompatibility and performance.

There are recent product launches that are manufactured using the latest technologies. For instance, in June 2024, Medtronic plc, a global leader in healthcare technology, announced the launch of its latest innovation in cardiac surgery, the Avalus Ultra valve. This next-generation surgical aortic tissue valve is designed to facilitate ease of use at implant and lifetime patient management. It's an excellent choice for cardiac surgeons and their patients seeking an aortic valve solution that can be fit for the future, right from the start.

High costs of procedures and devices

Factors such as high costs of procedures and devices are expected to hamper the global heart valve devices market. One of the primary issues is the significant price burden involved with cardiac valve procedures, particularly modern technology like transcatheter aortic valve replacement (TAVR). These treatments frequently include not only the cost of the devices themselves, but also additional costs such as preoperative imaging, hospital stays, and postoperative care. These high costs can make it difficult for many patients, particularly those in low- and middle-income areas or without adequate insurance coverage, to get the therapies they need. As a result, the financial implications may discourage patients from obtaining prompt treatment, reducing total market demand.

For instance, according to the National Institute of Health, The median out-of-pocket expenditure for valve replacement surgery using mechanical and bio-prosthetic valves was estimated to be INR107,800 (US$1684) and INR154,000 (US$2406), respectively, and for balloon valvotomy was estimated to be INR14,456 (US$367). Overall package cost per mechanical and bio-prosthetic single valve replacement surgery and balloon valvotomy procedure was estimated as INR127,919 (US$1999), INR148,919 (US$2372) and INR14,456 (US$226), respectively.

Segment Analysis

The global heart valve devices market is segmented based on heart valve replacement devices, position, heart valve repair devices, end-user, and region.

TMVR (Transcatheter Mitral Valve Replacement) segment is expected to dominate the global heart valve devices market share

The TMVR (Transcatheter Mitral Valve Replacement) segment is anticipated to dominate the global heart valve devices market owing to its growing importance in treating mitral valve disorders, technological advancements, recent launches and approvals, and increase in the number of mitral regurgitations. As people live longer, the prevalence of age-related heart diseases, including MR, increases, needing better treatment options. TMVR provides a less intrusive alternative to standard surgical techniques, making it especially appealing to patients who are at high risk of complications from open-heart surgery. This shift toward less intrusive procedures is consistent with general trends in healthcare, which show an increasing preference for interventions that shorten recovery time and hospital stays. For instance, with a global prevalence of over 2%, mitral regurgitation is a common valvular abnormality with various causes, including congenital conditions, rheumatic fever, and degenerative changes in the valve.

Technological advances in TMVR devices have also led to their projected market dominance. Recent advances have resulted in the creation of more complex and dependable equipment that improves procedural success rates and patient outcomes. These developments include improved valve designs that provide greater hemodynamic performance and biocompatibility, as well as upgraded delivery systems that make implantation easier. As these technologies advance, they are projected to gain broader acceptability among healthcare practitioners and patients, increasing demand for TMVR solutions.

For instance, in May 2024, 4C Medical Technologies, a Minnesota-based medical device company focused on structural heart disease, received the FDA's breakthrough device designation for its AltaValve System for transcatheter mitral valve replacement (TMVR). The supra-annular AltaValve System was designed to treat both primary and secondary mitral regurgitation (MR) patients. It is implanted via transseptal access and positioned above the native mitral valve when implanted.

Geographical Analysis

North America is expected to hold a significant position in the global heart valve devices market share

North America will likely account for a significant share of the global heart valve devices market, owing to its advanced healthcare infrastructure, a high prevalence of cardiovascular disorders, technological advancements, and recent launches and approvals. The rising prevalence of cardiovascular disorders needs novel solutions, fueling demand for heart valve devices that can restore normal heart function and improve patient outcomes.

For instance, according to the National Institute of Health, approximately 82.6 million people in the United States currently have one or more forms of cardiovascular disease (CVD), making it a leading cause of death for both men and women. Common types of cardiovascular disease include coronary heart disease (CHD), stroke, hypertension, and congestive heart failure. An estimated 16.3 million Americans aged 20 and older have CHD, a prevalence of 7 percent. The prevalence for men is 8.3 percent and for women is 6.1 percent. About 7 million Americans aged 20 or older have had a stroke. Each year approximately 610,000 experience their first stroke and another 185,000 experience a recurrence. Approximately 87 percent of all strokes are ischemic of which 10 percent result from intracerebral hemorrhage and 3 percent result from subarachnoid hemorrhage.

The region has established itself as a pioneer in the use of advanced medical technologies, particularly in cardiovascular care. One of the most significant developments is the invention and execution of transcatheter heart valve replacement (TAVR) operations, which have transformed the therapeutic landscape for patients with aortic stenosis and other valvular disorders. TAVR is a minimally invasive alternative to standard open-heart surgery that allows for faster recovery and shorter hospital stays, which is especially useful for older patients or those with complications.

For instance, in December 2024, Heart valve developer Anteris Technologies made its U.S. stock market debut one of the few initial public offerings by a MedTech company. The successful funding from this IPO is projected to considerably boost Anteris' capabilities in creating minimally invasive cardiac solutions, aligning with the increasing demand for cardiac surgery in aging populations.

Asia Pacific is growing at the fastest pace in the global heart valve devices market

The Asia Pacific region is emerging as the fastest-growing market for heart valve devices, owing to a combination of demographic trends, increased healthcare investment, recent launches, technological advancements, and a rising number of cardiovascular disorders. Cardiovascular diseases (CVDs) continue to be a prominent cause of morbidity and mortality globally, and their prevalence is significantly increasing in the Asia Pacific area. Inactive lifestyles, poor dietary habits, smoking, and increased stress are all contributing factors to this growth.

For instance, according to the National Institute of Health, annual number of deaths from CVD in India is projected to rise from 2.26 million (1990) to 4.77 million (2020). Coronary heart disease prevalence rates in India have been estimated over the past several decades and have ranged from 1.6% to 7.4% in rural populations and from 1% to 13.2% in urban populations.

Competitive Landscape

The major global players in the global heart valve devices market include Abbott, Medtronic, Artivion, Inc., Boston Scientific Corporation, Micro Interventional Devices, Edwards Lifesciences Corporation, Sorin Medical Group, TTK Heartvalve, JenaValve, Lepu Medical Technology (Beijing)Co., Ltd. among others.

Emerging Players

Capstan Medical, Vesalius Cardiovascula, and Orchestra BioMed among others

Key Developments

• In November 2024, Meril Life Sciences Pvt Ltd. launched its next-generation transcatheter heart valve (THV), the Myval Octapro THV, which it says allows for better operator control for precise positioning and improved predictability in implantation. The new valve was launched in spite of the company's differences with Edwards Lifesciences Corp. in a European court over patent infringement of its technology.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global heart valve devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Heart Valve Replacement Devices
• 3.2. Snippet by Position
• 3.3. Snippet by Heart Valve Repair Devices
• 3.4. Snippet by End-User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
  • 4.1.2. Increasing Demand for Heart Valve Devices
  • 4.1.3. Restraints
  • 4.1.4. High Costs of Procedures and Devices
  • 4.1.5. Opportunity
  • 4.1.6. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Heart Valve Replacement Devices

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Heart Valve Replacement Devices
  • 6.1.2. Market Attractiveness Index, By Heart Valve Replacement Devices
• 6.2. Mechanical Valve*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Bioprosthetic Valve
• 6.4. TAVR

7. By Position

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Position
  • 7.1.2. Market Attractiveness Index, By Position
• 7.2. Mitral Valve*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Aortic Valve
• 7.4. Others

8. By Heart Valve Repair Devices

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Heart Valve Repair Devices
  • 8.1.2. Market Attractiveness Index, By Heart Valve Repair Devices
• 8.2. Surgical Valve*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Balloon Valvuloplasty Devices
• 8.4. TMVR

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Ambulatory Surgical Centers
• 9.4. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Heart Valve Replacement Devices
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Position
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Heart Valve Repair Devices
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Heart Valve Replacement Devices
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Position
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Heart Valve Repair Devices
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Heart Valve Replacement Devices
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Position
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Heart Valve Repair Devices
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Heart Valve Replacement Devices
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Position
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Heart Valve Repair Devices
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Heart Valve Replacement Devices
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Position
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Heart Valve Repair Devices
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Abbott*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Medtronic
• 12.3. Artivion, Inc
• 12.4. Boston Scientific Corporation
• 12.5. Micro Interventional Devices
• 12.6. Edwards Lifesciences Corporation
• 12.7. Sorin Medical Group
• 12.8. TTK Heartvalve
• 12.9. JenaValve
• 12.10. Lepu Medical Technology (Beijing)Co., Ltd.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us